The OncoDaily Multiple Myeloma Congress 2026 is a global virtual medical congress dedicated to multiple myeloma, focusing on early diagnosis, risk stratification, multidisciplinary treatment strategies, and future directions in disease management and control.
Multiple Myeloma remains a significant and growing global health challenge, representing approximately 0.9% of all newly diagnosed cancers and 1.2% of cancer-related deaths worldwide, according to estimates from the World Health Organization (WHO) and the Global Burden of Disease (GBD) study. Recent data suggest that nearly 188,000 new cases are diagnosed each year globally, with over 120,000 deaths attributed to the disease, based on GLOBOCAN and GBD analyses. In the United States alone, around 36,000 new cases are expected in 2026, according to the American Cancer Society, highlighting the continued burden of this plasma cell malignancy.
Scientific Program Overview
This focused virtual meeting will explore the full clinical spectrum of multiple myeloma, emphasizing practical, experience-based management in 2026. The program will address contemporary approaches to suspected and newly diagnosed disease through risk-adapted decision-making, as well as evidence-based strategies for relapsed and refractory myeloma. Sessions will examine structured treatment principles that guide daily clinical practice, including the selection of systemic therapies, the sequencing of novel agents, multidisciplinary coordination, and individualized patient care.
The OncoDaily Multiple Myeloma Congress 2026 is designed for hematologists, medical oncologists, hematopathologists, radiologists, radiation oncologists, translational researchers, and oncology trainees seeking a practical and globally informed perspective on multiple myeloma management in 2026.
Myelo 2026 Event Details
Date: April 23, 2026
Format: Virtual Global Congress
Registration: Link to Register
Live Streaming: YouTube | X